Passage Bio Inc. (PASG): Price and Financial Metrics

Passage Bio Inc. (PASG): $1.86

0.10 (+5.68%)

POWR Rating

Component Grades













Add PASG to Watchlist
Sign Up

Industry: Biotech



in industry

PASG Stock Price Chart Interactive Chart >

Price chart for PASG

PASG Price/Volume Stats

Current price $1.86 52-week high $16.14
Prev. close $1.76 52-week low $1.57
Day low $1.69 Volume 303,600
Day high $1.88 Avg. volume 379,124
50-day MA $2.49 Dividend yield N/A
200-day MA $6.26 Market Cap 101.01M

Passage Bio Inc. (PASG) Company Bio

Passage Bio, Inc. operates as a genetic medicines company. It focuses on developing transformative therapies for rare, monogenic central nervous system disorders with limited or no approved treatment options. The company assembles a portfolio of genetic medicine products, which includes PBGM01 for the treatment of GM1, PBFT02 for the treatment of FTD and PBKR03 for the treatment of Krabbe disease. Passage Bio was founded by Stephen P. Squinto, Tadataka Yamada, David A. Socks, Aditya Kohli, and James M. Wilson in July 2017 and is headquartered in Philadelphia, PA.

PASG Latest News Stream

Event/Time News Detail
Loading, please wait...

PASG Latest Social Stream

Loading social stream, please wait...

View Full PASG Social Stream

Latest PASG News From Around the Web

Below are the latest news stories about Passage BIO Inc that investors may wish to consider to help them evaluate PASG as an investment opportunity.

Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022

PHILADELPHIA, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical-stage genetic medicines company focused on developing transformative therapies for central nervous system disorders, today announced that it will host a conference call and live webcast at 8:30 a.m. ET on Thursday, March 3, 2022 to report its fourth quarter and full-year 2021 financial results and discuss recent business highlights. To access the live conference call, please dial 833-528-0605 (domestic)

Yahoo | February 24, 2022

Passage Bio (PASG) Presents At 2022 WORLD Symposium Data Conference

No summary available.

Seeking Alpha | February 14, 2022

Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposium

Both children with late infantile GM1 gangliosidosis in Cohort 1 of the Imagine-1 clinical trial showed developmental improvement in assessments by study investigators and caregivers Interim safety data at three and nine months in Imagine-1 showed low dose PBGM01 well tolerated with no serious adverse events reported and no evidence of dorsal root ganglion toxicity First patients dosed in Cohort 2 (late infantile with high dose PBGM01) and Cohort 3 (early infantile with low dose PBGM01); anticipate reporting initial biomarker and safety data in 2H2022 Management to host conference call and webcast on Friday, February 11 at 1 p.m. ET PHILADELPHIA, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG ), a clinical-stage genetic medicines company focused on developing transfor...

Benzinga | February 11, 2022

Passage Bio (PASG) Presents At J.P. Morgan 40th Annual Healthcare Conference

No summary available.

Seeking Alpha | February 3, 2022

What Kind Of Investors Own Most Of Passage Bio, Inc. (NASDAQ:PASG)?

If you want to know who really controls Passage Bio, Inc. ( NASDAQ:PASG ), then you'll have to look at the makeup of...

Yahoo | February 1, 2022

Read More 'PASG' Stories Here

PASG Price Returns

1-mo -7.00%
3-mo -45.93%
6-mo -73.91%
1-year -85.96%
3-year N/A
5-year N/A
YTD -70.71%
2021 -75.17%
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.4008 seconds.